BioWorld Asia

May 18, 2005

NovImmune, Serono Enter Antibody Deal Worth $122M

NovImmune SA entered its first product out-licensing pact, a deal with Serono SA, which is potentially worth up to $122 million for two preclinical fully human antibodies, NI-0401 and NI-0501. (BioWorld International) Read More

To Increase Pipeline, CAT Pushing Back Profitability

Positive Results At ASCO For Nicotine Vaccine Raise Hopes

AC Immune Gets CHF21M For Sensitive Antibodie

Initiatives Aim To Make UK Top Spot For Clinical Trials

Intec Pharma Gets New CEO, Plans 'Accordion Pill' Program

Law On Agricultural Biotech Stuck In German Parliament

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan. 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 13, 2025

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

BioWorld

The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...

Proteomics study explores how protein changes influence disease

BioWorld Science

Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

BioWorld

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...